| Dr Melissa C Smith, MD | |
|
2811 E 2nd St, Austin, TX 78702-4843 | |
| (512) 324-4973 | |
| (512) 324-4948 |
| Full Name | Dr Melissa C Smith |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 2811 E 2nd St, Austin, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225049166 | NPI | - | NPPES |
| 111433201 | Other | TX | MEDICAID EPSDT |
| 043785701 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | K0203 (Texas) | Primary |
| Entity Name | Santa Barbara County County Auditor |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134162613 PECOS PAC ID: 9335052083 Enrollment ID: O20031107000729 |
News Archive
Researchers have identified a genetic test that when used with DNA testing would detect a higher number of genetic mutations in colorectal cancer patients, according to a study in the February 16 issue of JAMA, a theme issue on medical applications of biotechnology.
When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.
Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled "PI-3 Kinase Inhibitor Prodrugs." This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore's clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.
Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.
Kwashiorkor, one of the most extreme forms of malnutrition, is estimated to affect more than a hundred thousand children annually.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Melissa C Smith, MD 3706 S 1st St, Austin, TX 78704-7046 Ph: (512) 324-4973 | Dr Melissa C Smith, MD 2811 E 2nd St, Austin, TX 78702-4843 Ph: (512) 324-4973 |
News Archive
Researchers have identified a genetic test that when used with DNA testing would detect a higher number of genetic mutations in colorectal cancer patients, according to a study in the February 16 issue of JAMA, a theme issue on medical applications of biotechnology.
When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.
Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled "PI-3 Kinase Inhibitor Prodrugs." This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore's clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.
Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.
Kwashiorkor, one of the most extreme forms of malnutrition, is estimated to affect more than a hundred thousand children annually.
› Verified 2 days ago
Robert Obrien, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4316 James Casey St, Bldg F200, Austin, TX 78745 Phone: 512-791-7555 | |
Jason B Holinbeck, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1301 W 38th St Ste 102, Austin, TX 78705 Phone: 512-454-4561 Fax: 512-406-7330 | |
David L. Purtle, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1921 Lohmans Crossing Rd Ste 150, Austin, TX 78734 Phone: 737-717-8430 Fax: 737-717-8469 | |
Dr. Jared Kealy, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 6937 N Interstate 35 Ste 2, Austin, TX 78752 Phone: 877-800-5722 | |
Dr. Barbara Lynne Gray, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12505 Hymeadow Dr, Suite 2a, Austin, TX 78750 Phone: 512-219-8991 Fax: 512-219-8996 | |
Dr. Albert Edward Meisenbach Iii, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 100 West Dean Keeton, Austin, TX 78712 Phone: 512-475-8335 Fax: 512-471-0898 | |
Dr. Kanakadurga Govindaraju, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4107 Spicewood Springs Rd Ste 100, Austin, TX 78759 Phone: 512-397-3360 Fax: 512-343-7107 |